Skip to main
PRTA
PRTA logo

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Prothena Corp PLC's clinical pipeline shows promising results in reducing amyloid levels with its investigational therapeutics, positioning the company favorably in the treatment landscape for neurodegenerative and rare diseases. The company has guided that it is on track to potentially earn up to $105 million in aggregate milestones by 2026, driven by advancements in its partnered programs with Novo Nordisk and Bristol-Myers Squibb. Additionally, despite some concerns related to elevated ARIA incidence in one of its treatments, the overall tolerability and low incidence of injection-site reactions bodes well for patient compliance and market acceptance of its therapies.

Bears say

Prothena Corp faces several significant challenges that contribute to a negative outlook on its stock. The company is expected to continue incurring net losses until product approval and commercialization, likely requiring additional capital which could dilute shareholder value. Furthermore, uncertainties surrounding regulatory approvals and potential changes to the regulatory landscape pose additional risks that could hinder the company's progress and financial performance.

Prothena (PRTA) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 8 analysts, Prothena (PRTA) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.